Introduction {#s1}
============

Osteonecrosis of the femoral head (ONFH) is caused by the obstruction or interruption of local blood supply, resulting in tissue ischemia, necrosis, and finally bone collapse (Kim et al., [@B22]). The core decompression method only relieved the pressure of the pulp cavity and delayed the progression of necrosis (Yu et al., [@B44]). At present, long-term and/or large-dose use of steroids have become the most important risk factors for non-traumatic ONFH (Shigemura et al., [@B32]). The pathogenesis of steroid-induced ONFH (SONFH) is not yet clear and may be related to an imbalance in lipid metabolism and abnormal microcirculation (Johnson et al., [@B20]). The abnormal blood supply leads to apoptosis of osteocytes and osteoblasts, which causes bone loss and reduces bone mineral density (Luo et al., [@B27]). In addition, disordered lipid metabolism is another crucial pathogenesis that leads to increases in circulating lipid levels, microvascular fat embolisms, and lipid accumulation in the pulp cavity and ultimately causes osteocyte death.

Genetic polymorphisms have been found to be related to SONFH due to individual differences. Studies exploring the association between single-nucleotide polymorphisms (SNPs) and SONFH will help to identify the high SONFH risk population who use steroids. For these patients, it is necessary to avoid steroid application or to change the application strategy, increase the frequency of detection of SONFH, and enable early intervention. Furthermore, genetic variant-related studies can help to understand the pathogenesis of SONFH. Presently, several meta-analyses have been published that indicate that *PAI-1* rs1799768 (Gong et al., [@B13]), ABCB1 rs1045642 (Gong et al., [@B13]; Li et al., [@B25]; Zhou et al., [@B50]), and CYP3A variants (Guo and Deng, [@B14]) are related to the occurrence of SONFH. However, there is still a dispute over ABCB1 rs2032582 (Gong et al., [@B13]; Li et al., [@B25]; Zhou et al., [@B50]). This study will explicitly exclude studies in which the control group includes a healthy population or other types of ONFH; only comparison studies between ONFH and non-ONFH in the steroid use population are included. Because all studies are based on case-control and cohort designs with low evidence levels, we also used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines to assess the outcomes (Guyatt et al., [@B15]). Overall, the relationship between genetic variants and steroid-induced osteonecrosis of the femoral head in steroid use populations will be assessed in this study.

Methods {#s2}
=======

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines (Moher et al., [@B28]).

Data source and search strategy
-------------------------------

Two authors independently performed a literature search using PubMed, Embase, the Cochrane Library, and the Chinese public databases, including the China National Knowledge Infrastructure (CNKI), the China Biology Medicine (CBM) Database, the China Science Periodical Database (CSPD, Wanfang Database), and the VIP Journal Integration Platform (VJIP). Searches were performed for studies published up to April 15, 2018. The following terms were used in the search strategy: hormone, glucocorticoid, steroid, corticosteroid, osteonecrosis, necrosis, femoral, femur, femoris, whirlbone, polymorphism, SNP, genetic, mutation, genotype, allele, allelic, and variation. We also conducted manual searches of the reference lists of relevant reviews to avoid omissions.

Selection criteria
------------------

The following studies were included in our meta-analysis if they fulfilled the inclusion criteria: (1), study has a case-control or cohort study design; (2), steroid-using patients are included; (3), study compares ONFH and non-ONFH patients after steroid use; (4), study assesses the association between SNPs and SONFH; and (5), study indicates the frequencies of specific alleles or the effect sizes of individual genotypes between cases and controls.

The exclusion criteria included the following: (1), study compares patients with SONFH to healthy populations or populations with other types of ONFH; (2), study is about family heredity; (3), study is not SNP-related; and (4), study does not report data pertaining to allelic frequencies or calculable effect size. In addition, conference reports, editor comments, reviews, and academic dissertations were also excluded from the analysis.

Data extraction and quality assessment
--------------------------------------

Two authors independently extracted the following information from each eligible study: the first author\'s name, publication year, research location, sample size, average age, primary disease, diagnostic mode, and genes of interest. The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale (NOS), a validated tool for evaluating the quality of observation studies that includes the following 3 subscales: selection, comparability, and exposure (Stang, [@B33]). We assessed all results for the level of evidence using the GRADE approach (Andrews et al., [@B1]), the average NOS score, and the number of patients included and then presented the data in a three-dimensional Manhattan plot.

Statistical analysis
--------------------

The Hardy-Weinberg equilibrium (HWE) of the included populations was calculated to assess the consistencies of allele frequencies between generations (Chen and Chatterjee, [@B8]). Association analysis was performed using five genetic models (Areeshi et al., [@B2]). The effect size was estimated by calculating the summary odds ratio (OR) and its 95% confidence intervals (CIs). The *I*^2^ statistic was used to estimate the degree of heterogeneity among the studies. If the *I*^2^ ≥ 50% (Q test, *p* \< 0.1), a random-effect model was used; otherwise, a fixed-effect model was used. Subgroup analysis was also performed according to the ethnicity and location of the population. We assessed publication bias using the Begg and Egger tests. All tests were two-tailed, and a *p-*value of less than 0.05 was deemed statistically significant. We analyzed the data using the R program (Version 3.3.1) and STATA (Version 14.0).

We used GRADE to assess the level of evidence with four levels graded from high (best) to very low (worst). All objective studies used an observational study design, which downgrades the quality of evidence. Inconsistency was evaluated using the *I*^2^ and *p-*values of the Q test, and the outcome was imprecise if the standard error (SE) was larger than 0.2. Publication bias (reporting bias) also reduced the level of evidence. Finally, a large (OR \> 2 or \<0.5) or very large (OR \> 5 or \<0.2) effect upgraded the quality of evidence.

Results {#s3}
=======

Our research returned 278 English articles and 285 Chinese articles after removing duplications. After screening the titles and abstracts, 482 of these articles were excluded. The full texts of 81 articles were assessed, among which the control group did not receive steroid therapy (25); the article was a review (7); the study was non-SNP-related (5); the research was basic (3); the study did not report frequencies or effect size results (2); the study did not include steroid-related ONFH (2); the study was a case report (2); the research was microRNA related (2); the report was a duplicate (2); and the research was of heredity SONFH (1). Finally, we collected 30 trials assessing 7,553 patients for our meta-analysis (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

###### 

Characteristics of the included studies.

  **References**               **Local**       **Sample size**   **Average age[^\#^](#TN1){ref-type="table-fn"}**   **Type of steroids**               **Primary disease**                                                           **Genes**                                                            **NOS score**
  ---------------------------- --------------- ----------------- -------------------------------------------------- ---------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------- ---------------
  Zhao et al., [@B49]          China           193 (78/115)      40 (18--48)                                        Prednisone                         SLE; ALL; RT; LT; NS; RA; AS                                                  *GRG*                                                                9
  Plesa et al., [@B29]         Caucasian       304 (32/272)      NA                                                 Prednisone                         ALL                                                                           *BCL2L11*                                                            9
  Karol et al., [@B21]         Multinational   2955 (400/2555)   NA                                                 Prednisone; dexamethasone          ALL etc.                                                                      GWAS                                                                 7
  Wei et al., [@B39]           China           75 (45/30)        39 ± 10                                            Prednisone                         SLE; NS; ENT; dermatologic disease                                            *ApoA1; ApoB; ApoE*                                                  8
  Zhang et al., [@B47]         China           200 (94/106)      44.5 (18--82)                                      Prednisolone                       Hematologic; dermatologic; renal; ophthalmopathy; respiratory disease, etc.   *ABCB1*                                                              7
  Xue et al., [@B40]           China           322 (105/217)     39 (18--48)                                        Prednisone                         SLE; ALL; OT                                                                  *ABCB1*                                                              9
  Cui et al., [@B9]            China           424 (223/201)     42.27 ± 15.71                                      Prednisolone                       NA                                                                            *ApoA5*                                                              7
  Zeng et al., [@B45]          China           206 (108/98)      40 ± 10                                            Prednisone                         SLE; NS; RT; Purpura; ENT; dermatologic disease                               *ApoB*                                                               8
  Zhang et al., [@B48]         China           200 (94/106)      44.5 (18--82)                                      Prednisolone                       Hematologic; dermatologic; renal; ophthalmopathy; respiratory disease, etc.   *PAI-1*                                                              7
  Wang et al., [@B36]          China           200 (94/106)      44.5 (18--82)                                      Prednisolone                       Hematologic; dermatologic; renal; ophthalmopathy; respiratory disease, etc.   *PON-1*                                                              6
  Li et al., [@B24]            China           123 (70/53)       29 (18--73)                                        Prednisone                         NA                                                                            *ABCB1*                                                              6
  Wei, [@B37]                  China           134 (63/71)       35.17 ± 11.73                                      Prednisone                         NA                                                                            *ApoB; CYP1A2*                                                       8
  Wei, [@B38]                  China           134 (63/71)       35.17 ± 11.73                                      Prednisone                         NA                                                                            *Factor V; GR; CBP; ApoB; CYP1A2*                                    8
  Bond et al., [@B6]           UK              110 (43/67)       NA                                                 Dexamethasone                      ALL                                                                           *PAI-1*                                                              8
  He and Li, [@B16]            China           48 (31/17)        32 (12--59)                                        NA                                 Hemoglobinopathies                                                            *CYP3A4; ABCB1*                                                      7
  He and Li, [@B17]            China           48 (31/17)        18--60                                             Prednisone                         SLE; RA; psoriasis; nephropathy; desmosis, etc.                               *CYP3A4*                                                             7
  Kuribayashi et al., [@B23]   Japan           157 (34/123)      35 (9--64)                                         Methylprednisolone; prednisolone   RT                                                                            *ABCB1; ApoB; CBP*                                                   9
  French et al., [@B12]        USA             361 (51/310)      NA (10--20)                                        Prednisone; dexamethasone          ALL                                                                           *ABCB1; PAI-1* et al. 11 Genes[^\#\#^](#TN2){ref-type="table-fn"}    7
  Wang et al., [@B35]          China           53 (16/37)        35 (16--78)                                        Methylprednisolone                 RT                                                                            *TNF-α*                                                              8
  Tamura et al., [@B34]        Japan           157 (34/123)      35 (9--64)                                         Methylprednisolone; prednisolone   RT                                                                            *GR; CYP3A4; CBP; NCoA2*                                             9
  Yang and Xu, [@B42]          China           127 (21/106)      34 (11--67)                                        Methylprednisolone; prednisone     SLE                                                                           *ABCB1*                                                              9
  Hirata et al., [@B19]        Japan           112 (20/92)       NA                                                 Methylprednisolone; prednisone     SLE                                                                           *ApoA*                                                               7
  Hirata et al., [@B18]        Japan           158 (34/124)      36.1 (9--64)                                       Methylprednisolone; prednisolone   RT                                                                            *ApoB*                                                               7
  Ekmekci et al., [@B10]       Turkey          57 (19/38)        34.2 ± 9.3                                         NA                                 RT                                                                            *Factor V; Prothrombin*                                              7
  Celik et al., [@B7]          Turkey          50 (11/39)        41 ± 11.79                                         Prednisolone                       RT                                                                            *Factor V; Prothrombin; MTHFR*                                       8
  Relling et al., [@B30]       USA             64 (25/39)        8.6 (2.7--18.8)                                    Prednisone                         ALL                                                                           *MDR1(ABCB1)* et al. 13 Genes[^\#\#\#^](#TN3){ref-type="table-fn"}   8
  Asano et al., [@B5]          Japan           137 (31/106)      36 (9--63)                                         Methylprednisolone; prednisolone   RT                                                                            *PAI-1; MTHFR*                                                       8
  Asano et al., [@B3]          Japan           80 (26/54)        NA                                                 NA                                 RT                                                                            *CYP3A4; CYP2D6; CYP2C19*                                            7
  Asano et al., [@B4]          Japan           136 (30/106)      35.5 (9--63)                                       Methylprednisolone; prednisolone   RT                                                                            *ABCB1*                                                              8
  Ferrari et al., [@B11]       Switzerland     228 (26/202)      50 ± 12                                            Prednisone                         RT                                                                            *PAI-1*                                                              8

*ALL, Acute lymphoblastic leukemia; AS, Ankylosing spondylitis; ENT, Ear, nose, and throat; GWAS, Genome-wide association study; LT, Liver transplant; NA, Not available; NOS, Newcastle-Ottawa Scale; NS, Nephrotic syndrome; OT, Organ transplant; RA, Rheumatic arthritis; RT, Renal transplant; SLE, Systemic lupus erythematosus*.

*: Mean ± Standard deviation; Mean/Median (Minimum-Maximum)*.

*: TYMS; VDR; BGLAP; ESR1; LRP5; MTHFR; PAI-1; ABCB1(MDR1); PTH; PTHR; ACP5*.

*: CYP3A4; CYP3A5; TPMT; UGT1A1; TYMS; GSTT1; GSTM1; RFC; MTHFR; GRG(NR3C1); MDR1(ABCB1); VDR; GSTP1*.

![PRISMA flow chart illustrating the selection process of the studies included in our analysis. SNP, single-nucleotide polymorphism; SONFH, steroid-induced osteonecrosis of the femoral head.](fphys-09-01684-g0001){#F1}

All studies used a case-control design except one that used a cohort design (Karol et al., [@B21]). In addition, Weibao Fang\'s two studies (Wei, [@B37],[@B38]), and Kuribayashi and Tamura\'s studies (Tamura et al., [@B34]; Kuribayashi et al., [@B23]) included the same patient population but did not assess the same SNPs. We analyzed different SNP results and excluded duplicated results. The NOS scores were six to nine points, and the overall quality was ideal in observational studies (Table [1](#T1){ref-type="table"}).

Six SNPs in four genes were included in the meta-analysis. In the ABCB1 gene, rs1045642 is also known as C3435T, is located in the coding region, and is a synonymous mutation. In this research, the pooled results for rs1045642 showed that the C \> T mutation protected against SONFH in the allelic model (*I*^2^ = 50.2%; OR: 0.74; 95% CI: 0.55--1.00; *p* = 0.046) (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). In the ApoB gene, rs693 is located in the coding region. The results showed that there was no significant relationship between this mutation and SONFH in the allelic model (*I*^2^ = 58%; OR: 2.63; 95% CI: 0.92--7.54; *p* = 0.072). However, other models showed that this mutation could increase SONFH risk (heterozygous model: *I*^2^ = 54.5%; OR: 2.46; 95% CI: 1.27--4.77; *p* = 0.008; homozygous model: *I*^2^ = 24.4%; OR: 7.70; 95% CI: 1.23--48.16; *p* = 0.029; dominant model: *I*^2^ = 31.4%; OR: 2.99; 95% CI: 1.71--5.21; *p* \< 0.001; recessive model: *I*^2^ = 32.1%; OR: 7.16; 95% CI: 1.19--43.02; *p* = 0.031). rs1042031 could cause a missense mutation of glutamic acid to lysine or stop-gain mutation. Only the dominant model was analyzed, and the results showed that there was a significant relationship between this mutation and SONFH (*I*^2^ = 50.3%; OR: 2.90; 95% CI: 1.49--5.66; *p* = 0.002). Three studies were from China, and subgroup analysis results also indicated a significant relationship (*I*^2^ = 0%; OR: 4.81; 95% CI: 2.05--11.31; *p* \< 0.001) (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Forest plot of associations between mutations and SONFH risk. SNP, single-nucleotide polymorphism; SONFH, steroid-induced osteonecrosis of the femoral head.](fphys-09-01684-g0002){#F2}

###### 

Meta-analysis of the associations between SNPs and SONFH in the SNP results in more than three studies.

  **Gene**   **Location**    **SNP/HWE test**   **Model**                **No. of study**   **Sample size**   **OR**     **LCI**    **UCI**     ***P-*value**   ***I*^2^**   ***P* for *I*^2^**   **Begg\'stest**   **Egger\'stest**
  ---------- --------------- ------------------ ------------------------ ------------------ ----------------- ---------- ---------- ----------- --------------- ------------ -------------------- ----------------- ------------------
  *ABCB1*    Multinational   rs1045642          **Allelic model**        **8**              **1141**          **0.74**   **0.55**   **1.00**    **0.046**       **50.20%**   **0.02**             **0.902**         **0.797**
                                                Heterozygous model       8                  1141              0.80       0.61       1.06        0.117           0%           0.758                1                 0.891
                             Case: 0.4946       Homozygous model         8                  1141              0.48       0.20       1.15        0.101           67.10%       0.006                0.548             0.458
                             Control: 0.0423    Dominant model           9                  1420              0.78       0.61       1.00        0.051           3.80%        0.403                0.602             0.838
                             Total: 0.0209      Recessive model          8                  1141              0.57       0.24       1.37        0.21            71.80%       0.002                0.548             0.427
  *ABCB1*    China           rs1045642          Allelic model            5                  790               0.84       0.54       1.31        0.434           67.00%       0.017                0.806             0.664
                                                Heterozygous model       5                  790               0.83       0.60       1.15        0.263           0.00%        0.803                0.806             0.427
                             Case: 0.3666       Homozygous model         5                  790               0.64       0.18       2.27        0.493           79.00%       0.003                1                 0.934
                             Control: 0.106     Dominant model           5                  790               0.78       0.57       1.06        0.111           11.90%       0.338                0.462             0.518
                             Total:0.0473       Recessive model          5                  790               0.72       0.21       2.47        0.601           80.40%       0.002                1                 0.889
  *ABCB1*    Multinational   rs2032582          Allelic model            7                  964               0.85       0.58       1.23        0.382           63.40%       0.012                1                 0.517
                                                Heterozygous model       7                  964               0.78       0.56       1.08        0.138           11.70%       0.34                 1                 0.042
                             Case:0.0034        Homozygous model         7                  964               0.68       0.32       1.42        0.3             60.10%       0.028                0.707             0.731
                             Control:0.2588     Dominant model           7                  964               0.81       0.59       1.10        0.167           39.30%       0.13                 1                 0.227
                             Total:0.0055       Recessive model          7                  964               0.85       0.45       1.63        0.633           62.20%       0.021                0.707             0.804
  *ABCB1*    China           rs2032582          Allelic model            5                  764               0.97       0.60       1.59        0.914           70.60%       0.009                0.806             0.408
                                                Heterozygous model       5                  764               0.80       0.55       1.15        0.231           41.00%       0.148                1                 0.077
                             Case:0.0021        Homozygous model         5                  764               0.85       0.32       2.24        0.742           69.70%       0.019                1                 0.99
                             Control:0.4073     Dominant model           5                  764               0.82       0.45       1.51        0.528           57.70%       0.051                0.806             0.238
                             Total:0.009        Recessive model          5                  764               1.10       0.49       2.44        0.819           68.30%       0.024                1                 0.87
  *ApoB*     Multinational   rs693              Allelic model            4                  570               2.63       0.92       7.54        0.072           58.00%       0.068                1                 0.67
                                                **Heterozygous model**   **4**              **570**           **2.46**   **1.27**   **4.77**    **0.008**       **54.50%**   **0.111**            **1**             **0.461**
                             Case:0.0027        **Homozygous model**     **4**              **570**           **7.70**   **1.23**   **48.16**   **0.029**       **24.40%**   **0.25**             **1**             **NA**
                             Control:0.2173     **Dominant model**       **5**              **725**           **2.99**   **1.71**   **5.21**    \<**0.001**     **31.40%**   **0.212**            **0.624**         **0.82**
                             Total:0.0003       **Recessive model**      **4**              **570**           **7.16**   **1.19**   **43.02**   **0.031**       **32.10%**   **0.225**            **1**             **NA**
  *ApoB*     China           rs693              Allelic model            3                  415               2.82       0.51       15.57       0.235           72.20%       0.028                1                 0.77
                                                Heterozygous model       3                  415               1.59       0.32       7.86        0.57            70.20%       0.067                1                 NA
                             Case:0.0008        Homozygous model         3                  415               16.17      0.89       293.00      0.06                                                                
                             Control:1          Dominant model           3                  415               2.41       0.54       10.82       0.252           62.40%       0.07                 1                 0.881
                             Total:0.0005       Recessive model          3                  415               16.17      0.89       293.00      0.06                                                                
  *ApoB*     Multinational   rs1042031          **Dominant model**       **4**              **572**           **2.90**   **1.49**   **5.66**    **0.002**       **50.30%**   **0.11**             **0.308**         **0.146**
  *ApoB*     China           rs1042031          **Dominant model**       **3**              **415**           **4.81**   **2.05**   **11.31**   \<**0.001**     **0.00%**    **0.886**            **1**             **0.769**
  *MTHFR*    Multinational   rs1801133          Allelic model            3                  251               0.92       0.59       1.44        0.71            12.90%       0.317                1                 0.401
                                                Heterozygous model       3                  251               0.62       0.33       1.18        0.144           22.10%       0.277                1                 0.549
                             Case:0.0713        Homozygous model         3                  251               1.24       0.48       3.22        0.653           0%           0.744                1                 NA
                             Control: 0.8662    Dominant model           4                  507               0.94       0.61       1.45        0.775           23.40%       0.271                0.308             0.203
                             Total:0.3016       Recessive model          3                  251               1.54       0.63       3.75        0.339           0%           0.964                1                 NA
  *PAI-1*    Multinational   rs1799768          Allelic model            3                  485               0.55       0.23       1.35        0.193           83.90%       0.002                0.296             0.021
                                                Heterozygous model       3                  485               0.47       0.19       1.16        0.099           68.10%       0.043                1                 0.937
                             Case: 0.0016       Homozygous model         3                  485               0.38       0.07       2.03        0.258           77.50%       0.012                0.296             0.069
                             Control: 0.3961    Dominant model           3                  485               0.44       0.14       1.34        0.146           82.80%       0.003                0.296             0.107
                             Total: 0.0066      Recessive model          3                  485               0.60       0.17       2.13        0.429           63.50%       0.064                0.296             0.151

*SNP, single-nucleotide polymorphism; SONFH, steroid-induced osteonecrosis of the femoral head; OR, odds ratio; LCI, lower confidence intervals; UCI, upper confidence intervals; HWE, Hardy--Weinberg equilibrium. Bold characters indicate that the p value is less than 0.05*.

The level of evidence of the above positive results was assessed according to GRADE guidelines. The allelic model of ABCB1 rs1045642 showed a protective effect against SONFH. In these results, 1,141 patients were included; the average NOS score was 7.88. Although the SE was relatively small, there was heterogeneity (*I*^2^ = 50.2%, *p* = 0.02). Thus, the level of evidence was very low (Figure [3](#F3){ref-type="fig"}). The heterozygous model and dominant model of ApoB rs693 showed that the mutation increases SONFH risk. The SE of the two models was smaller than 0.2, and heterogeneity was not obvious (heterozygous model: *I*^2^ = 54.5%, *p* = 0.111; dominant model: *I*^2^ = 31.40%, *p* = 0.212). The level of evidence was moderate because of the large effect (OR\>2) (Figure [3](#F3){ref-type="fig"}). The homozygous and recessive models of ApoB rs693 also showed that the mutation increases disease risk without heterogeneity (homozygous model: *I*^2^ = 24.4%, *p* = 0.25; recessive model: *I*^2^ = 32.1%, *p* = 0.225). Although the SEs were larger than 0.2, the OR was greater than 5. Thus, the evidence levels were also moderate (Figure [3](#F3){ref-type="fig"}). In addition, the average NOS scores of these four models were 8 to 8.25. The dominant model of ApoB rs1042031 indicated that the mutation increases SONFH risk without heterogeneity (*I*^2^ = 50.3%, *p* = 0.11). The SE of the result was less than 0.2, and the OR was greater than 2. Thus, the level of evidence was moderate (Figure [3](#F3){ref-type="fig"}). However, the genetic linkage disequilibrium that exists in the above positive results might affect stability.

![A three-dimensional Manhattan plot showing the average NOS score, the number of included patients, and the level of evidence. The green bar indicates the protection effect, and the red bar indicates the promotion effect.](fphys-09-01684-g0003){#F3}

Discussion {#s4}
==========

Our study analyzed the association between genetic polymorphisms and SONFH risk by comparing ONFH and non-ONFH in steroid use populations. In the SNP results of the included studies, more than three allelic models of ABCB1 rs1045642 showed that mutations protect against SONFH. The ApoB rs693 and rs1042031 mutations increase SONFH risk. According to the GRADE guidelines, the evidence levels for ApoB rs693 and rs1042031 were moderate, and ABCB1 rs1045642 was very low.

In a previous meta-analysis, Gong et al analyzed 23 studies and 35 genes and indicated that PAI-1 rs1799768 and ABCB1 rs1045642, but not MTHFR rs1801133 or ABCB1 rs2032582, were related to the risk of osteonecrosis (Gong et al., [@B13]). However, in this study, the control population included a healthy group and a population with other types of ONFH, which might affect the accuracy. In our study, there was no relationship between PAI-1 rs1799768 after adjusting for the control population. Guo et al assessed the correlation between SONFH and hepatic CYP3A activity and high found that CYP3A activity could reduce SONFH risk. However, the conclusion was based on animal model results, and it is unclear whether the risk is reduced in humans (Guo and Deng, [@B14]).

ABCB1 is a member of a superfamily of ATP-binding cassette transporters that transport variant molecules across cellular membranes. Zhou et al. researched the association between ABCB1 polymorphisms and SONFH and found that rs1045642 and rs2032582 are associated with SONFH (Zhou et al., [@B50]). However, this study also included a healthy population in the control population. In contrast, a Chinese review showed that rs1045642 could reduce SONFH risk, while rs2032582 is not related to SONFH (Yang J. et al., [@B41]). For rs1045642, our results are the same as those of a previous study, but with a very low level of evidence. The mutation does not cause changes in the amino acid sequence; thus, the specific mechanism of SONFH risk change caused by this mutation is still unknown. However, this mutation has been shown to be related to the metabolism of some drugs and to the prognosis of some cancers. This relationship may be related to differences in the characteristics of non-expressed proteins, such as codon bias, expression efficiency, and differences in mRNA characteristics. Therefore, this mutation is more suitable for clinical use as a predictor of SONFH risk for steroid users to guide individual drug application. People with the rs1045642 T allele have a low risk of SONFH with steroid application, while individuals with C allele have a high SONFH risk and should avoiding long-term high-dose steroid application, with increased duration of follow-up and frequency of diagnosis. For rs2032582, our results found that the mutation is not related to SONFH (allelic model: *p* = 0.382) with statistical heterogeneity (*I*^2^ = 63.4%, *p* = 0.012).

Additionally, we performed a *post hoc* analysis of Seth E. Karol\'s research that excluded SNP results with very low-level evidence (Karol et al., [@B21]). Then, we matched potential SNPs with GO/KEGG annotations (Table [3](#T3){ref-type="table"}). According to a gene set enrichment analysis based on overrepresentation enrichment analysis, only the molecular functions of ABCB1 and ApoB showed obvious relationships with lipid transporter activity (GO: 0005319) (Zhang et al., [@B46]). This finding indicates that at present, SNPs involved in lipid transporter activity are more related to SONFH risk than other SNPs, which supports the lipid metabolism disorder theory. ApoB is an important factor in normal lipid metabolism, the mutation of which can also be used as a predictor of SONFH occurrence to assess the risk of SONFH and to guide steroid clinical application. Although rs693 is a synonymous variant, rs693 is related to the circulating concentration of LDL cholesterol. T allele carriers have high levels of TG, TC, and LDL-C and low HDL-C (Sandhu et al., [@B31]). In addition, rs1042031 is a coding sequence variant that causes glutamate to lysine mutation (C \> T), or the introduction of a stop codon in the amino acid sequence (C \> A). The rs1042031 mutation is important for regulating the binding of apolipoprotein B to the LDL cholesterol receptor (Liu et al., [@B26]). In this work, these two mutations were found to be related to SONFH. Therefore, we hypothesized that the increase of circulating LDL induced by mutation increased the risk of SONFH, supporting the hypothesis that lipid metabolism disorders are associated with SONFH. Abnormal lipid metabolism leads to bone marrow adipogenesis of the femoral head that is mainly due to hyperlipidemia and inhibition of mitochondrial dehydrogenation by steroid application. The abnormal lipid metabolism then leads to fat embolism, which blocks local blood perfusion and exacerbates local inflammation. Therefore, the question remains: does reducing circulating LDL effectively reduce the risk of SONFH with steroid application? In animal models, it has been suggested that reduced circulating lipid levels can reduce the risk of SONFH (Yang Z. et al., [@B43]), but the clinical effect remains to be confirmed. Additionally, in the location subgroup analysis of rs1042031 results, the heterogeneity decreased significantly from 50 to 0%. The pool results of the three Chinese studies had low heterogeneity, and the population was concentrated in Guangxi and Shandong in China (Wei, [@B37]; Zeng et al., [@B45]; Wei et al., [@B39]). Another study analyzed the Japanese population (Hirata et al., [@B18]). Therefore, the centralization of the included population may be the main reason for the reduction in heterogeneity.

###### 

GO and KEGG annotations of possibly related genes for SONFH in this research.

  **Genes**                                  **Gene name**                                             **Biological process**                                                                                                                                                                                       **Molecular function**                                                                                                  **Cell component**                                                          **KEGG**
  ------------------------------------------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------
  *ABCB1[^\#^](#TN4){ref-type="table-fn"}*   ATP-binding cassette subfamily B member 1                 lipid localization;regulation of membrane lipid distribution                                                                                                                                                 lipid transporter activity; drug transporter activity                                                                   Apical part of cell                                                         ABC transporters; Bile secretion
  *APOB[^\#^](#TN4){ref-type="table-fn"}*    Apolipoprotein B                                          Macromolecular complex remodeling;Lipid localization;Foam cell differentiation;Protein-lipid complex subunit organization;Response to inorganic substance;Regulation of plasma lipoprotein particle levels   Lipid transporter activity; Lipoprotein particle receptor binding                                                       Endoplasmic reticulum lumen;Protein-lipid complex;Cell body;Vesicle lumen   Vitamin digestion and absorption; Fat digestion and absorption
  *BAZ2A*                                    Bromodomain adjacent to zinc finger domain 2A             NA                                                                                                                                                                                                           Ligand-dependent nuclear receptor binding                                                                               Transcriptional repressor complex                                           NA
  *KLF12*                                    Kruppel-like factor 12                                    NA                                                                                                                                                                                                                                                                                                                                                                                                               
  *GRIN3A*                                   Glutamate ionotropic receptor NMDA type subunit 3A        NA                                                                                                                                                                                                           Glutamate receptor activity; Metal ion transmembrane transporter activity; Passive transmembrane transporter activity   Transporter complex;Cell body                                               Nicotine addiction; Cocaine addiction; Amphetamine addiction
  *COL22A1*                                  Collagen type XXII alpha 1 chain                          NA                                                                                                                                                                                                           NA                                                                                                                      Endoplasmic reticulum lumen;collagen trimer                                 NA
  *FAT1*                                     FAT atypical cadherin 1                                   NA                                                                                                                                                                                                           NA                                                                                                                      NA                                                                          NA
  *CABIN1*                                   Calcineurin-binding protein 1                             NA                                                                                                                                                                                                           Phosphatase regulator activity                                                                                          Inclusion body                                                              NA
  *AMPD1*                                    Adenosine monophosphate deaminase 1                       Cellular metabolic compound salvage                                                                                                                                                                          Deaminase activity; Myosin binding                                                                                      NA                                                                          NA
  *KCNMA1*                                   Potassium calcium-activated channel subfamily M alpha 1   Renal system process;Response to inorganic substance;Excretion                                                                                                                                               Metal ion transmembrane transporter activity; Passive transmembrane transporter activity                                Transporter complex;Apical part of cell                                     Renin secretion; Insulin secretion; Salivary secretion
  *PCSK5*                                    Proprotein convertase subtilisin/kexin type 5             Renal system process                                                                                                                                                                                         NA                                                                                                                      Golgi lumen                                                                 NA

*The gene results are based on traditional meta-analysis; others are based on Genome Wide Association Study-related meta-analysis*.

Limitations
-----------

The present study still has several limitations. First, our study was performed at the study level instead of the individual level. Second, our study did not consider the impact of primary disease or steroid therapy strategies on the results. Third, there is a large amount of heterogeneity in the results of this study. Although random effect models are used for heterogeneous results, these heterogeneities can still have a potential impact on the results. Fourth, our study only analyzed the SNPs that were examined in more than three studies, but with new research and evidence, more SNPs may be studied. Therefore, this study was limited by the research available at the time.

Conclusion {#s5}
==========

An allelic model of ABCB1 rs1045642 showed that mutations had a protective effect against SONFH at a very low level of evidence. The mutations in ApoB rs693 and rs1042031 increased the SONFH risk with moderate levels of evidence.
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